Drugs / Liposomal Alendronate
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00739466 | Sep 2008 → Dec 2015 | coronary stenosis | BIOrest Ltd. | Completed | Missed primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Liposomal Alendronate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00739466 ↗ |
| Route | Intravenous | “Patients were randomized to receive LABR-312 at 2 dose levels or placebo as an intravenous infusion during percutaneous coronary intervention and bare metal stent implantation.” PMID 23351827 ↗ Dec 2012 |